Shirley, NY- Luitpold Animal Health, a division of Luitpold Pharmaceuticals, Inc., manufacturers of Adequan® IM, Adequan® IA, and Adequan® Canine provides the following supply update:

We are pleased to announce a shipment of Adequan® (polysulfated glycosaminoglycan) IM was released to the market last week and was received by veterinarians beginning Friday, September 13th . Adequan® product supply remains limited and the initial shipments will not fully satisfy market demand. Luitpold made significant investments in upgrading its manufacturing facilities earlier this year. The time spent making these upgrades impacted our ability to keep up with demand. We are working diligently to release additional product to the market and will provide updates as they become available. Quality and integrity remain our highest priorities.

We encourage Adequan® users to continue to work with their veterinarians to obtain the drug and discuss the most appropriate treatment regimen for your animals.

Luitpold has established a dedicated webpage on www.adequan.com where concerned parties can register to receive future communications and updates on this matter. You may also contact our Customer Service Department at 1-800-458-0163.

Adequan® IM and IA are the only polysulfated glycosaminoglycan (PSGAG) approved by the FDA for the treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness in horses. Adequan® Canine is the only polysulfated glycosaminoglycan (PSGAG) approved by the FDA for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.